| Trial ID # | NCT00429793 |
| Phase | II |
| Drug Class | Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR |
| Drug Name | Temsirolimus |
| Alternate Drug Names | Torisel, CCI-779 |
| Drugs in Trial | Temsirolimus |
| Eligible Participant | Persistent or recurrent ovarian cancer, 1-3 prior cytoxic therapies |
| Patients Enrolled | 54; median 2 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, OS, evaluated per RECIST |
| Biomarkers | Exploratory: p-AKT, p-mTOR, p-4EBP1, pp70-S6K, Cyclin D1, CTC |
| Efficacy | ORR: 9.3% (5PR) |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Modest activity; phase III not warranted in unselected patients; CCND1 positivity associated with longer PFS |
| Reference | Behbakht K et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 123(1):19-26 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.